Retatrutide: Is It Time to Panic? Lilly's Lawsuits, the Science, and What Happens Next

Podcast: Peptides Explained · John Garrett

Opublikowano: 2026-10-19

Eli Lilly is taking legal action against businesses selling products labeled retatrutide. What do the lawsuits actually establish—and what don't they? John Garrett separates pending legal allegations from court findings, reviews the human trial evidence for the investigational triple agonist, and explains why molecular identity, purity, and pharmaceutical equivalence are not interchangeable. We also examine FDA restrictions, consumer safety, and the implications for clinics, vendors, and independent educators. Educational only; not medical or legal advice. Retatrutide is not FDA-approved. Sources: NEJM DOI 10.1056/NEJMoa2301972; FDA unapproved GLP-1 drug concerns; ClinicalTrials.gov NCT05929066 and NCT05882045.